– Based on FDA confirmation in
August 2023 that the ongoing Phase
1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal
study to support BLA submission under an accelerated approval
request, the Company has expedited efforts to attain commercial
readiness –
– Full results of the Phase
1 portion of the ongoing Phase 1/2 study of PRGN-2012 were
published in the peer-reviewed journal, Science Translational
Medicine, and presented in an oral presentation at the ESGCT 30th
Annual Congress –
– Enrollment and dosing was
completed in the Phase 2 study of PRGN-2012 in RRP; Phase 2 study
completion expected in the second quarter of
2024 –
– Cash, cash equivalents,
short-term and long-term investments totaled $79.0 million as of September 30, 2023; cash runway projected into
2025 –
– Continued focus on cost
containment resulted in a reduction in SG&A costs of 17% for
the nine months ended September 30,
2023, compared to the prior year over the same period
–
GERMANTOWN, Md., Nov. 9, 2023
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical
company specializing in the development of innovative gene and cell
therapies to improve the lives of patients, today announced third
quarter 2023 financial results and progress of clinical
programs.
"Precigen has made tremendous progress in reducing our operating
costs and we are actively reprioritizing our programs to enable
commercial readiness for our lead asset, PRGN-2012. We anticipate
completing the PRGN-2012 Phase 2 study in the second quarter of
2024 and, given the FDA's guidance in August
2023 that the ongoing Phase 1/2 study of PRGN-2012 will
serve as the pivotal study to support an accelerated approval
request, we are working to expedite the submission of a BLA as
quickly as possible," said Helen
Sabzevari, PhD, President and CEO of Precigen. "We have
recently published exciting new data for both of the Company's core
platforms, AdenoVerse and UltraCAR-T, including presentations at
the ESGCT 30th Annual Congress for PRGN-3007 UltraCAR-T and
PRGN-2012 AdenoVerse immunotherapy, and publication of a manuscript
in Science Translational Medicine that includes full Phase 1
data from the PRGN-2012 clinical study. Each publication builds the
body of clinical evidence for the potential of our innovative
therapeutic platforms in meeting unmet medical needs for
patients."
Program Highlights
PRGN-2012 AdenoVerse™ Immunotherapy in RRP
- PRGN-2012 is an investigational off-the-shelf AdenoVerse
immunotherapy designed to elicit immune responses directed against
cells infected with human papillomavirus (HPV) 6 or HPV 11 for the
treatment of recurrent respiratory papillomatosis (RRP). The US
Food and Drug Administration (FDA) has granted Breakthrough Therapy
Designation and Orphan Drug Designation for PRGN-2012 for the
treatment of RRP.
- The Company announced that the FDA has agreed that the ongoing
Phase 1/2 (NCT04724980) single-arm study will serve as pivotal for
the purpose of filing an accelerated approval request for
licensure. Based on this FDA guidance, the Company plans to
initiate a confirmatory study prior to submission of the biologics
license application (BLA).
- The Company presented positive Phase 1 data showing clinical
benefit and enhanced T-cell responses with repeated administration
from the ongoing Phase 1/2 single-arm study at the European Society
of Gene & Cell Therapy (ESGCT) 30th Annual Congress in an oral
presentation (Abstract# OR04) titled, "Significant clinical
benefit and enhanced T-cell responses with repeated administration
of PRGN-2012, a novel gorilla adenoviral vector based
immunotherapy, in adult patients with severe recurrent respiratory
papillomatosis."
- The presentation included full results of the Phase 1 study and
add to the previously presented data for PRGN-2012 which showed
significant response in RRP patients with 50% of patients in
Complete Response, requiring no post-treatment surgeries, following
PRGN-2012 treatment at Dose Level 2 with a favorable safety
profile, no dose-limiting toxicities and no treatment-related
adverse events (TRAEs) greater than Grade 2.
- Complete Responses are durable and all complete responders
remain surgery-free (follow-up range: 18-24 months) after PRGN-2012
treatment completion.
- PRGN-2012 treatment induced robust HPV-specific T cell
responses which were correlated with clinical responses in the
study.
- Full results of the Phase 1 portion of the ongoing Phase 1/2
study of PRGN-2012 were published in the peer-reviewed journal,
Science Translational Medicine, a leading publication from
the American Association for the Advancement of Science (AAAS), in
a manuscript titled, "The tumor microenvironment state
associates with response to HPV therapeutic vaccination in patients
with respiratory papillomatosis."
- Enrollment and dosing in the Phase 2 portion of the study
(N=23) is complete bringing the total number of enrolled patients
to 35 at Dose Level 2. Patient follow up is currently ongoing and
the Phase 2 study is expected to be complete by the second quarter
of 2024.
PRGN 2009 AdenoVerse™ Immunotherapy in HPV-associated
Cancers
- PRGN-2009 is an investigational off-the-shelf AdenoVerse
immunotherapy designed to activate the immune system to recognize
and target HPV-positive solid tumors.
- The Company completed the Phase 1 (NCT04432597) study and
presented positive Phase 1 clinical data from the monotherapy and
combination therapy arms in patients with recurrent or metastatic
HPV-associated cancers at the 2023 American Society of Clinical
Oncology (ASCO) Annual Meeting.
- Enrollment was completed in the Phase 2 monotherapy arm with 20
evaluable patients in newly diagnosed oropharyngeal squamous cell
carcinoma (OPSCC) patients. The Phase 2 (NCT05996523) combination
arm (PRGN-2009 in combination with pembrolizumab) in
OPSCC is enrolling patients.
- The Company plans to initiate a Phase 2 randomized, open-label,
two-arm study of PRGN-2009 in combination with pembrolizumab in
patients with recurrent or metastatic cervical cancer.
PRGN-3006 UltraCAR-T® in AML
- PRGN-3006 is an investigational multigenic, autologous chimeric
antigen receptor T (CAR-T) cell therapy engineered to express a CAR
specifically targeting CD33, membrane bound IL-15 (mbIL15), and a
kill switch. The FDA granted Orphan Drug Designation and Fast Track
Designation for PRGN-3006 UltraCAR-T for patients with relapsed or
refractory acute myeloid leukemia (AML).
- The Company completed the Phase 1 (NCT03927261) dose escalation
study and presented positive data at the 64th American Society of
Hematology (ASH) Annual Meeting and Exposition.
- The Phase 1b dose expansion study
of PRGN-3006 is ongoing and an interim clinical data presentation
is expected in 2024.
PRGN-3005 UltraCAR-T® in Ovarian Cancer
- PRGN-3005 UltraCAR-T is an investigational multigenic,
autologous CAR-T cell therapy engineered to express a CAR
specifically targeting the unshed portion of MUC16, mbIL15, and a
kill switch.
- The Company completed the Phase 1 (NCT03907527) dose escalation
cohorts of the intraperitoneal (IP) and intravenous (IV) arms
without lymphodepletion as well as in the lymphodepletion cohort in
the IV arm and presented positive Phase 1 clinical data in patients
with advanced platinum resistant ovarian cancer at the 2023 ASCO
Annual Meeting.
- As previously communicated, based on portfolio reprioritization
efforts, the Company will not add an extensive number of new sites
this year. Instead, a new site will be activated under the
Cooperative Research and Development Agreement (CRADA) with the
National Cancer Institute (NCI) to continue the advancement of the
PRGN-3005 Phase 1b dose expansion
study without incurring major clinical/contract research
organization (CRO) costs.
PRGN-3007 UltraCAR-T® in Advanced ROR1+
Hematological and Solid Tumors
- PRGN-3007, based on the next generation of the UltraCAR-T
platform, is an investigational multigenic, autologous CAR-T cell
therapy engineered to express a CAR targeting receptor tyrosine
kinase-like orphan receptor 1 (ROR1), mbIL15, a kill switch, and a
novel mechanism for the intrinsic blockade of PD-1 gene
expression.
- The Phase 1 dose escalation portion of the Phase 1/1b study is ongoing. The target patient
population for the Phase 1/1b study
includes ROR1+ advanced hematological and solid tumors.
- The Company presented additional preclinical data (Abstract#
P469) for PRGN-3007 at the ESGCT 30th Annual Congress in a poster
presentation titled, "Overnight-manufactured UltraCAR-T® cells
with first-in-class miRNA-based PD1 blockade demonstrates enhanced
polyfunctionality and sustained cytotoxicity against hematological
and solid tumors."
Financial Highlights
- Cash, cash equivalents, short-term and long-term investments
totaled $79.0 million as of
September 30, 2023.
- Selling, general, and administrative (SG&A) costs decreased
versus the prior year, by 9% and 17% for the three and nine months
ended September 30, 2023,
respectively.
"Following our portfolio reprioritization and other cost-saving
measures announced last quarter, Precigen continues to manage the
balance sheet to enable rapid progression of our lead assets," said
Harry Thomasian Jr., CFO of
Precigen. "As we scale-up areas of our business to prepare for
commercialization, we are focused on fiscal management and
exploring new non-dilutive capital opportunities, including
potential strategic partnerships, to maximize and extend our
runway."
Third Quarter 2023 Financial Results Compared to Prior Year
Period
Research and development expenses decreased
$1.0 million, or 8%, compared to the
three months ended September 30,
2022. This decrease was primarily due to continued
reprioritization of clinical product candidates.
SG&A expenses decreased $0.9
million, or 9%, compared to the three months ended
September 30, 2022. This decrease was
primarily driven by a reduction in professional fees of
$0.6 million, due to decreased legal
fees associated with certain litigation matters, and $0.3 million in decreased insurance related
expenses.
Total revenues decreased $15.3
million, or 92%, compared to the three months ended
September 30, 2022. Collaboration and
licensing revenues decreased $14.6
million, or 100%, compared to the three months ended
September 30, 2022, primarily due to
the prior year period non-cash recognition of revenue related to
historical collaboration agreements for which revenue was
previously deferred. Product and service revenues decreased
$0.7 million, or 34%, compared to the
three months ended September 30,
2022. This decrease is related to reductions in services
performed at Exemplar.
Total other income, net, increased $2.1
million compared to the three months ended September 30, 2022. This is primarily due to
$2.0 million in reduced interest
expense associated with the Company's Convertible Notes as they
were fully retired in the second quarter of 2023, and $0.8 million increased interest income due to
higher interest rates on investments. This increase was offset by a
$0.9 million gain recorded on the
early retirement of a portion of the Convertible Notes in the third
quarter of 2022 that did not occur in the third quarter of
2023.
Loss from continuing operations was $19.8
million, or $(0.08) per basic
and diluted share, compared to loss from continuing operations of
$7.6 million, or $(0.04) per basic and diluted share, in the three
months ended September 30, 2022.
First Nine months 2023 Financial Results Compared to Prior
Year Period
Research and development expenses decreased
$0.8 million, or 2%, compared to the
nine months ended September 30, 2022.
This decrease was primarily due to continued reprioritization of
clinical product candidates.
SG&A expenses decreased $6.3
million, or 17%, compared to the nine months ended
September 30, 2022. This decrease was
primarily driven by a reduction in professional fees of
$4.8 million, due to decreased legal
fees associated with certain litigation matters, as well as a
$1.2 million reduction in salaries,
benefits, and other personnel costs due to reduced head count, and
$0.3 million in decreased insurance
related expenses.
Total revenues decreased $20.1
million, or 80%, from the nine months ended September 30, 2022. Collaboration and licensing
revenues decreased $14.6 million or
100% from the nine months ended September
2022, primarily due to the prior year period non-cash
recognition of revenue related to historical collaboration
agreements for which revenue was previously deferred. Product and
services revenues decreased $5.4
million, or 52%, from the nine months ended September 30, 2022. This decrease primarily
related to reductions in services performed at Exemplar as well as
the recognition of revenue in the first quarter of 2022 related to
agreements for which revenue was previously deferred that did not
occur in 2023 of $1.0 million at
Exemplar.
Total other income, net, increased $7.3
million compared to the nine months ended September 30, 2022. This is primarily due to
$5.7 million reduced interest expense
associated with the Convertible Notes as they were retired in the
second quarter of 2023, and $2.1
million increased interest income due to higher interest
rates on the Company's investments. This increase was offset by
$0.8 million reduction in the gain
recorded on the early retirement of a portion of the Convertible
Notes in 2023 compared to 2022.
Loss from continuing operations was $62.8
million, or $(0.26) per basic
and diluted share, compared to loss from continuing operations of
$57.6 million, or $(0.29) per basic and diluted share, in the nine
months ended September 30, 2022.
Precigen: Advancing Medicine with
Precision™
Precigen (Nasdaq: PGEN) is a dedicated
discovery and clinical stage biopharmaceutical company advancing
the next generation of gene and cell therapies using precision
technology to target the most urgent and intractable diseases in
our core therapeutic areas of immuno-oncology, autoimmune
disorders, and infectious diseases. Our technologies enable us to
find innovative solutions for affordable biotherapeutics in a
controlled manner. Precigen operates as an innovation engine
progressing a preclinical and clinical pipeline of
well-differentiated therapies toward clinical proof-of-concept and
commercialization. For more information about Precigen, visit
www.precigen.com or follow us on X @Precigen, LinkedIn or
YouTube.
UltraCAR-T®
UltraCAR-T is a multigenic
autologous CAR-T platform that utilizes Precigen's advanced
non-viral Sleeping Beauty system to simultaneously express
an antigen-specific CAR to specifically target tumor cells, mbIL15
for enhanced in vivo expansion and persistence, and a kill
switch to conditionally eliminate CAR-T cells for a potentially
improved safety profile. Precigen has advanced the UltraCAR-T
platform to address the inhibitory tumor microenvironment by
incorporating a novel mechanism for intrinsic checkpoint blockade
without the need for complex and expensive gene editing techniques.
UltraCAR-T investigational therapies are manufactured via
Precigen's overnight manufacturing process using the proprietary
UltraPorator® electroporation system at the patient's
medical center and administered to patients only one day following
gene transfer. The overnight UltraCAR-T manufacturing process
does not use viral vectors and does not require ex vivo
activation and expansion of T cells, potentially addressing major
limitations of current T cell therapies.
UltraCAR-T® Clinical Program
Precigen's
UltraCAR-T platform is currently under clinical investigation for
hematological and solid tumors, including a Phase 1/1b study of PRGN-3005 UltraCAR-T in patients with
advanced, recurrent platinum resistant ovarian, fallopian tube or
primary peritoneal cancer (NCT03907527), a Phase 1/1b study of PRGN-3006 UltraCAR-T in patients with
relapsed or refractory acute myeloid leukemia (AML) or higher risk
myelodysplastic syndrome (MDS) (NCT03927261) and a Phase
1/1b study of PRGN-3007 UltraCAR-T
incorporating PD-1 checkpoint inhibition in patients with
ROR1-positive (ROR1+) chronic lymphocytic leukemia
(CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia
(ALL), diffuse large B-cell lymphoma (DLBCL) and triple negative
breast cancer (TNBC) (NCT05694364). PRGN-3006 UltraCAR-T has been
granted Orphan Drug Designation and Fast Track
Designation in patients with AML by the US Food and Drug
Administration (FDA).
UltraCAR-T® Library
Approach
Precigen's UltraCAR-T library approach is designed
to transform the personalized cell therapy landscape for cancer
patients. Precigen's goal is to develop and validate a library of
non-viral plasmids to target tumor-associated antigens. Enabled by
design and manufacturing advantages of UltraCAR-T, coupled with the
capabilities of the UltraPorator® system, Precigen is working
to empower medical centers to deliver personalized, autologous
UltraCAR-T treatment with overnight manufacturing to any cancer
patient. Based on the patient's cancer indication and biomarker
profile, one or more non-viral plasmids would be selected from the
library to build a personalized UltraCAR-T treatment. After initial
treatment, this approach has the potential to allow for redosing of
UltraCAR-T targeting the same or new tumor-associated antigen(s)
based on the treatment response and the changes in antigen
expression of the patient's tumor. Precigen believes that the
combination of the advanced UltraVector® DNA
construction platform and the ease of overnight manufacturing gives
this library approach a proprietary advantage over traditional
T-cell therapies.
UltraPorator®
The UltraPorator system is an
exclusive device and proprietary software solution for the scale-up
of rapid and cost-effective manufacturing of UltraCAR-T therapies
and potentially represents a major advancement over current
electroporation devices by significantly reducing the processing
time and contamination risk. The UltraPorator device is a
high-throughput, semi-closed electroporation system for modifying T
cells using Precigen's proprietary non-viral gene transfer
technology. UltraPorator is being utilized for clinical
manufacturing of Precigen's investigational UltraCAR-T therapies in
compliance with current good manufacturing practices.
AdenoVerse™ Immunotherapy
Precigen's
AdenoVerse immunotherapy platform utilizes a library of proprietary
adenovectors for the efficient gene delivery of therapeutic
effectors, immunomodulators, and vaccine antigens designed to
modulate the immune system. Precigen's gorilla adenovectors, part
of the AdenoVerse library, have potentially superior performance
characteristics as compared to current competition. AdenoVerse
immunotherapies have been shown to generate high-level and durable
antigen-specific T-cell immune responses as well as an ability to
boost these responses via repeat administration. Superior
performance characteristics and high yield manufacturing of
AdenoVerse vectors leveraging UltraVector® technology
allows Precigen to engineer cutting-edge investigational gene
therapies to treat complex diseases.
AdenoVerse™ Immunotherapy Clinical
Program
Precigen's AdenoVerse immunotherapy platform is
currently under clinical investigation in a Phase 1/2 study of
PRGN-2009 AdenoVerse immunotherapy alone or in combination with an
anti-PDL1/TGF-Beta Trap (bintrafusp alfa) in patients with
HPV-associated cancers (NCT04432597), including the Phase 2
combination arm (PRGN-2009 in combination with pembrolizumab) in
newly diagnosed patients with HPV-associated oropharyngeal
squamous cell carcinoma (OPSCC) (NCT05996523), and a Phase 1/2
study of PRGN-2012 AdenoVerse immunotherapy in patients with
recurrent respiratory papillomatosis (RRP) (NCT04724980). PRGN-2012
has been granted Orphan Drug Designation and Breakthrough
Therapy Designation in patients with RRP by the
FDA. Additionally, the FDA has cleared the IND to initiate a
Phase 2 study of PRGN-2009 AdenoVerse immunotherapy in combination
with pembrolizumab in patients with recurrent or metastatic
cervical cancer.
For patients interested in enrolling in NCI-led clinical
studies, please call NCI's toll-free number 1-800-4-Cancer
(1-800-422-6237) (TTY: 1-800-332-8615), email
NCIMO_Referrals@mail.nih.gov, and/or visit the website:
https://trials.cancer.gov.
Trademarks
Precigen, UltraCAR-T, UltraPorator,
AdenoVerse, UltraVector and Advancing Medicine with Precision are
trademarks of Precigen and/or its affiliates. Other names
may be trademarks of their respective owners.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release
are forward-looking statements. These forward-looking statements
are based upon the Company's current expectations and projections
about future events and generally relate to plans, objectives, and
expectations for the development of the Company's business,
including the timing and progress of preclinical studies, clinical
trials, discovery programs and related milestones, the promise of
the Company's portfolio of therapies, and in particular its CAR-T
and AdenoVerse therapies. Although management believes that the
plans and objectives reflected in or suggested by these
forward-looking statements are reasonable, all forward-looking
statements involve risks and uncertainties and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release. The Company has no
obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. For further information on potential risks
and uncertainties, and other important factors, any of which could
cause the Company's actual results to differ from those contained
in the forward-looking statements, see the section entitled "Risk
Factors" in the Company's most recent Annual Report on Form 10-K
and subsequent reports filed with the Securities and Exchange
Commission.
Investor Contact:
Steven M.
Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M.
Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
Precigen, Inc. and
Subsidiaries
|
Consolidated Balance
Sheets
|
(Unaudited)
|
(Amounts in
thousands)
|
September 30,
2023
|
December 31,
2022
|
Assets
|
|
|
Current
assets
|
|
|
Cash
and cash equivalents
|
$
10,076
|
$
4,858
|
Restricted cash
|
-
|
43,339
|
Short-term investments
|
63,679
|
51,092
|
Receivables
|
|
|
Trade,
net
|
988
|
978
|
Other
|
13,117
|
12,826
|
Prepaid expenses and other
|
5,128
|
5,066
|
Total current assets
|
92,988
|
118,159
|
Long-term in investments
|
5,271
|
-
|
Property, plant and equipment, net
|
7,115
|
7,329
|
Intangible assets, net
|
40,426
|
44,455
|
Goodwill
|
36,894
|
36,923
|
Right-of-use assets
|
7,197
|
8,086
|
Other assets
|
797
|
1,025
|
Total assets
|
$
190,688
|
$
215,977
|
Liabilities and
Shareholders' Equity
|
|
|
Current
liabilities
|
|
|
Accounts payable
|
$
2,351
|
$
4,068
|
Accrued compensation and benefits
|
6,621
|
6,377
|
Other accrued liabilities
|
4,119
|
4,997
|
Settlement and
indemnification accruals
|
18,075
|
18,750
|
Deferred revenue
|
509
|
25
|
Current portion of long-term debt
|
-
|
43,219
|
Current portion of lease liabilities
|
1,200
|
1,209
|
Total current liabilities
|
32,875
|
78,645
|
Deferred revenue, net of current portion
|
1,818
|
1,818
|
Lease liabilities, net of current portion
|
6,192
|
6,992
|
Deferred tax liabilities
|
2,125
|
2,263
|
Total liabilities
|
43,010
|
89,718
|
Shareholders'
equity
|
|
|
Common stock
|
-
|
-
|
Additional paid-in capital
|
2,082,654
|
1,998,314
|
Accumulated deficit
|
(1,931,415)
|
(1,868,567)
|
Accumulated other comprehensive loss
|
(3,561)
|
(3,488)
|
Total shareholders' equity
|
147,678
|
126,259
|
Total liabilities and shareholders' equity
|
$
190,688
|
$
215,977
|
Precigen, Inc. and
Subsidiaries
|
Consolidated
Statement of Operations
|
(Unaudited)
|
|
Three months
ended
|
Nine months
ended
|
(Amounts in
thousands, except share and per share data)
|
September 30,
2023
|
September 30,
2022
|
September 30,
2023
|
September 30,
2022
|
Revenues
|
|
|
|
|
Collaboration
and licensing revenues
|
$
-
|
$
14,561
|
$
-
|
$
14,561
|
Product
revenues
|
82
|
342
|
730
|
1,455
|
Service
revenues
|
1,296
|
1,750
|
4,261
|
8,896
|
Other
revenues
|
1
|
69
|
6
|
234
|
Total
revenues
|
1,379
|
16,722
|
4,997
|
25,146
|
Operating
Expenses
|
|
|
|
|
Cost of products and
services
|
1,537
|
1,577
|
4,761
|
5,082
|
Research and
development
|
11,583
|
12,622
|
35,620
|
36,377
|
Selling, general and
administrative
|
9,196
|
10,137
|
30,150
|
36,496
|
Impairment of
goodwill
|
-
|
-
|
-
|
482
|
Impairment of other
noncurrent assets
|
-
|
-
|
-
|
638
|
Total operating
expenses
|
22,316
|
24,336
|
70,531
|
79,075
|
Operating
loss
|
(20,937)
|
(7,614)
|
(65,534)
|
(53,929)
|
Other income
(Expense), Net
|
|
|
|
|
Interest
expense
|
(1)
|
(2,036)
|
(461)
|
(6,137)
|
Interest
income
|
856
|
56
|
2,316
|
131
|
Other income,
net
|
281
|
1,038
|
705
|
1,276
|
Total other income
(expense), net
|
1,136
|
(942)
|
2,560
|
(4,730)
|
Equity in net income
(loss) of affiliates
|
-
|
862
|
-
|
861
|
Loss from continuing
operations before income taxes
|
(19,801)
|
(7,694)
|
(62,974)
|
(57,798)
|
Income tax
benefit
|
6
|
50
|
126
|
197
|
Loss from continuing
operations
|
$
(19,795)
|
$
(7,644)
|
$
(62,848)
|
$
(57,601)
|
Income from
discontinued operations, net of income taxes
|
-
|
95,023
|
-
|
108,094
|
Net (loss)
income
|
$
(19,795)
|
$
87,379
|
$
(62,848)
|
$
50,493
|
Net (loss) income
per share
|
|
|
|
|
Net loss from
continuing operations per share, basic and diluted
|
$
(0.08)
|
$
(0.04)
|
$
(0.26)
|
$
(0.29)
|
Net income from
discontinued operations per share, basic and diluted
|
-
|
0.48
|
-
|
0.54
|
Net (loss) income per
share, basic and diluted
|
$
(0.08)
|
$
0.44
|
$
(0.26)
|
$
0.25
|
Weighted average shares
outstanding, basic and diluted
|
248,520,724
|
200,670,590
|
243,075,262
|
200,256,046
|
|
|
|
|
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-reports-third-quarter-2023-financial-results-and-progress-of-clinical-programs-301983843.html
SOURCE Precigen, Inc.